|
Synonyms: ALN-TTRsc04
Compound class:
Nucleic acid
Comment: Nucresiran (ALN-TTRsc04) is a small interfering RNA (siRNA) that is designed to target transthyretin (TTR) mRNA to reduce TTR expression. To improve pharmacokinetics, the nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, and it has a N-acetylgalactosamine (GalNAc) modified forward strand 5' end ("R" in the sequence provided) to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs).
|
| No information available. |
Summary of Clinical Use ![]() |
| Nucresiran was progressed as a clinical candidate for its potential to treat hereditary transthyretin-mediated amyloidosis. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05661916 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects | Phase 1 Interventional | Alnylam Pharmaceuticals | ||
| NCT07052903 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 Interventional | Alnylam Pharmaceuticals | ||
| NCT07223203 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | Phase 3 Interventional | Alnylam Pharmaceuticals | ||